U01EY030405
Cooperative Agreement
Overview
Grant Description
Dexamethasone as an effective therapy for ocular injuries by vesicating agents.
Grant Program (CFDA)
Awarding Agency
Place of Performance
Colorado
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 295% from $727,496 to $2,871,419.
The Regents Of The Univ. Of Colorado was awarded
Dexamethasone as an Effective Therapy for Ocular Injuries by Vesicating Agents.
Cooperative Agreement U01EY030405
worth $2,871,419
from the National Institute of Allergy and Infectious Diseases in August 2020 with work to be completed primarily in Colorado United States.
The grant
has a duration of 4 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01).
Status
(Complete)
Last Modified 8/21/23
Period of Performance
8/1/20
Start Date
7/31/24
End Date
Funding Split
$2.9M
Federal Obligation
$0.0
Non-Federal Obligation
$2.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U01EY030405
Transaction History
Modifications to U01EY030405
Additional Detail
Award ID FAIN
U01EY030405
SAI Number
U01EY030405-1157173978
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
MW8JHK6ZYEX8
Awardee CAGE
0P6C1
Performance District
CO-06
Senators
Michael Bennet
John Hickenlooper
John Hickenlooper
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $2,150,221 | 100% |
Modified: 8/21/23